Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Adding Veliparib to Chemotherapy Improves PFS in BRCA-Mutated Breast Cancer

Publish date:: October 21, 2019

Key clinical point: Adding veliparib to chemotherapy improves PFS in patients with BRCA-mutated breast cancer.

Major finding: Investigator-assessed median PFS: 14.5 vs. 12.6 months with veliparib vs. placebo (HR, 0.71).

Study details: The randomized, placebo-controlled phase 3 BROCADE 3 study of 509 patients.

Disclosures: AbbVie funded the study. Dr. Diéras reported advisory/consultancy roles for several pharmaceutical companies including AbbVie. Dr. Loi reported relationships with numerous pharmaceutical companies.

Citation:

Diéras V et al. ESMO 2019, Abstract LBA9.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Breast Cancer

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Study: Doctors underreport side effects of breast irradiation,

No edge for anastrozole over tamoxifen in DCIS,

Long-term APBI cosmetic, toxicity data reported WBI has the edge Practice-confirming results,

Omitting postop radiotherapy doesn’t affect survival in older breast cancer patients,